Cargando…

647. Adoption of the updated fluoroquinolones breakpoints for Gram negative bacteria in clinical microbiology laboratories

BACKGROUND: Despite the multiple safety warnings related to fluoroquinolones (FQs) treatment, their use remains unavoidable in several occasions due to their broad spectrum of coverage including activity against multi-drug resistant glucose non-fermenting Gram-negative bacteria such as Pseudomonas s...

Descripción completa

Detalles Bibliográficos
Autor principal:	Sfeir, Maroun M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776592/ http://dx.doi.org/10.1093/ofid/ofaa439.841

Ejemplares similares

1599. Clinical Outcomes for Patients Treated with Fluoroquinolones for Bacteremia Caused by Enterobacteriaceae Reclassified as Not Susceptible by Updated CLSI Breakpoints
por: Fleischner, Zachary, et al.
Publicado: (2020)

258. A Comparison of Cefprozil and Fluoroquinolones for Gram-Negative Bacteremia
por: Nolen, Rebecca C, et al.
Publicado: (2020)

1591. Updated Fluoroquinolone MIC Breakpoints: Impact on Susceptibility Rates in the United States
por: Flamm, Robert K, et al.
Publicado: (2019)

1787. County Level Association Between the Rate of Fluoroquinolone-Resistance Gram Negative Bacteria and Fluoroquinolone Utilization in Kansas
por: Fulmer, Robert D, et al.
Publicado: (2022)

Impact of Reappraisal of Fluoroquinolone Minimum Inhibitory Concentration Susceptibility Breakpoints in Gram-Negative Bloodstream Isolates
por: Shealy, Stephanie C., et al.
Publicado: (2020)

667. Multicenter Assessment of Enterobacterales, Salmonella spp. and Pseudomonas aeruginosa Using Updated CLSI Levofloxacin Breakpoints on MicroScan Dried Gram Negative MIC Panels
por: Garner, Omai, et al.
Publicado: (2020)

Updated EUCAST Clinical Breakpoints against Aspergillus, Implications for the Clinical Microbiology Laboratory
por: Guinea, Jesús
Publicado: (2020)

673. Updated CLSI Ciprofloxacin Breakpoints from a Multicenter Assessment for Enterobacterales, Salmonella spp. and Pseudomonas aeruginosa Using MicroScan Dried Gram Negative MIC Panels
por: Traczewski, Maria M, et al.
Publicado: (2020)

1549. Impact of New Fluoroquinolone Breakpoints on Enterobacteriaceae Susceptibility Rates and Clinical Outcomes
por: Pettit, Natasha N, et al.
Publicado: (2019)

271. Clinical Outcomes Treating Gram-Negative Bacteremia with Oral Beta-Lactams vs. Trimethoprim-Sulfamethoxazole or Fluoroquinolone Step-Down Therapy
por: Sinclair, Emily, et al.
Publicado: (2020)

356. Impact of CLSI Breakpoint Changes on Unit-Specific Combination Antibiograms for Gram-Negative Respiratory Isolates
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

2184. Effect of Adjusted CLSI Breakpoints on Center-wide Fluoroquinolone Susceptibilities for Enterobacteriaceae and Pseudomonas aeruginosa: Is It Time to Restrict Empiric Fluoroquinolone Use?
por: Sansom, Sarah, et al.
Publicado: (2019)

285. Evaluation of the ePlex® Blood Culture Identification (BCID) Panels for Gram-positive/Gram-negative bacteria and yeasts
por: Chapin, Kimberle, et al.
Publicado: (2020)

1355. Resistance in Gram-Negative Bacteria in the Pediatric Patient Population by Age and Sex
por: Malamet, Benjamin J, et al.
Publicado: (2020)

Improvement of Gram-negative Susceptibility to Fluoroquinolones After Implementation of a Pre-Authorization Policy for Fluoroquinolone Use: A Decade-Long Experience
por: Lee, Rachael A, et al.
Publicado: (2017)

832. Assessment of Risk Factors Associated with Wide-resistance Gram-negative Bacteria Infections
por: Reis, Henry Pablo Lopes Campos e, et al.
Publicado: (2020)

1034 Clinical Laboratory Practices in Speciating Organisms and Reporting Results of Voided Urine Cultures
por: Sfeir, Maroun, et al.
Publicado: (2014)

1371. Identification of Risk Factors to Predict Gram negative bacteria in Patients with Upper Extremity Infections
por: Zhitomirsky, Sophia, et al.
Publicado: (2021)

647. Diagnoses Associated with Temperature ≥104°F in Adults
por: Chi, Sharon, et al.
Publicado: (2019)

715 Impact of Fluoroquinolone Resistance on Community-Onset Gram-Negative Bloodstream Infections
por: Brigmon, Matthew, et al.
Publicado: (2014)

N1-Benzofused Modification of Fluoroquinolones Reduces Activity Against Gram-Negative Bacteria
por: Laws, Mark, et al.
Publicado: (2020)

Piperacillin-tazobactam vs. carbapenem for treating blood stream infections due to extended spectrum β-lactamase producing bacteria: Systematic review and meta-analysis
por: Sfeir, Maroun, et al.
Publicado: (2017)

230. Multicenter Assessment of the Accuracy of MIC Results for Colistin with MicroScan Dried Gram Negative MIC Panels using CLSI Breakpoints
por: Riedel, Stefan, et al.
Publicado: (2022)

A Dietary Source of High Level of Fluoroquinolone Tolerance in mcr-Carrying Gram-Negative Bacteria
por: Xu, Tianqi, et al.
Publicado: (2023)

Carbapenemases in Gram-Negative Bacteria: Laboratory Detection and Clinical Significance
por: Bedenić, Branka, et al.
Publicado: (2014)

1278. Testing the Synergistic Effect of Ceftazidime-Avibactam Plus Aztreonam on Metallobetalactamase-Producing Non-Fermenting Gram-negative Bacteria
por: Crouch, Elena M, et al.
Publicado: (2021)

Evaluation of the Accelerate Pheno™ System for the Identification and Antimicrobial Susceptibilty Testing of Gram-negative Bacteria, Compared with Conventional Laboratory Testing
por: Roulston, Kerry, et al.
Publicado: (2017)

166. Comparison of Oral Fluoroquinolones to Alternative Oral Agents for Definitive Step-Down Therapy in Gram-Negative Bloodstream Infections
por: Cho, Christian Y, et al.
Publicado: (2019)

647. Characterization and Development of Human Monoclonal Antibodies to Pneumococcal Serotype 3
por: Babb, Rachelle, et al.
Publicado: (2018)

1600. Closing the gap on moxifloxacin breakpoints for Stenotrophomonas maltophilia
por: Stone, Tyler J, et al.
Publicado: (2020)

Response of Caenorhabditis elegans during subsequent infections with Gram positive and Gram negative bacteria
por: Mercy, Gnanasekaran Jeba, et al.
Publicado: (2012)

1822. Clinical Outcomes Associated with Oral Beta-Lactam Therapy versus Oral Fluoroquinolones/TMP-SMX for Uncomplicated Gram-Negative Bacteremia
por: Kaur, Satwinder S, et al.
Publicado: (2022)

1121. Implementation and Evaluation of a Virtual Microbiology Laboratory for Pharmacy Students
por: Gruenberg, Katherine, et al.
Publicado: (2020)

2238. Effect of Cefazolin Breakpoint Update in Susceptibility Reports on Antimicrobial Use
por: Buckley, Valerie, et al.
Publicado: (2023)

Changing times: The impact of gram-negative breakpoint changes over the previous decade
por: Johnson, Wes M., et al.
Publicado: (2022)

911. Assessment of Representativeness of IPD Surveillance Conducted by the National Microbiology Laboratory of Canada
por: Nepal, Rajeev M, et al.
Publicado: (2020)

Endotoxin Activity Assay levels correlate with the microbiological results of Gram-negative organisms in septic patients
por: Tsunoda, M, et al.
Publicado: (2014)

P647: RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL
por: Rhodes, Joanna, et al.
Publicado: (2023)

1620. Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens
por: Shorttidge, Dee, et al.
Publicado: (2020)

Bloodstream infections caused by multidrug-resistant gram-negative bacteria: epidemiological, clinical and microbiological features
por: Leal, Helena Ferreira, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i6qpc0ukmingme4f7acta1dvpu